Ces radiol. 2011, 65(1):51-60

Imaging of the bone metastase with 18F-NaF-PET/CTReview article

Eva Ferdová1, Jiří Ferda1, Martin Vít Matějka2, Jindřich Fínek2
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Oddělení radoterapie a onkologie FN, Plzeň

Detection of the bone metastases belongs among the important problems of the staging in prostatic, breast and lung carcinoma and also others malignancies. The detection of the increased osteoblastic activity helps to assess the presence of bone metastatic disease including the monitoring of the disease activity. 18F-NaF-PET/CT becomes the alternative method to the bone scintigraphy in patients with suspected or present bone metastases dissemination. Thanks to the physical and physiological behavior, 18F shows the better bio-distribution parameters within the tissues especially in bone compared to 99mTc-methylendifosfonate. The review summarizes the potential of 18F-NaF-PET/CT as an alternative method to bone scintigraphy.

Keywords: 18F-NaF, 18F-NaF-PET/CT, bone scintigraphy, bone metastases, prostatic carcinoma

Accepted: January 15, 2011; Published: March 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferdová E, Ferda J, Matějka MV, Fínek J. Imaging of the bone metastase with 18F-NaF-PET/CT. Ces radiol. 2011;65(1):51-60.
Download citation

References

  1. Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32(3): 168-176. Go to original source... Go to PubMed...
  2. Strobel K, Fischer DR, Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, Johayem A, von Schulthess GK, Michel BA, Ciurea A. 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 2010; 37(9): 1760-1765. Go to original source... Go to PubMed...
  3. Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med 2010; 24(4): 241-247. Go to original source... Go to PubMed...
  4. Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007; 37(6): 462-469. Go to original source... Go to PubMed...
  5. Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36(11): 1807-1812. Go to original source... Go to PubMed...
  6. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2): 287-297.
  7. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36(1): 73-92. Go to original source... Go to PubMed...
  8. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004; 45(2): 272-278.
  9. Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR. Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med 2008; 49(3): 414-421. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.